Diligence memo · auto-generated · as of July 2, 2026
AuraSense Therapeutics, LLC
AuraSense Therapeutics, LLC looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
AuraSense Therapeutics, LLC operates in Biotechnology, based in Skokie.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
AuraSense Therapeutics, LLC has raised $34M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $15M on 2015-10-13.
Most recent recorded round closed around 2015-10-13.
Valuation (modeled)modeled
Provath models AuraSense Therapeutics, LLC at approximately $535M (range $16M–$2.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.36× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 23 months.
Last raise 10.7 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 76% of Biotechnology peers (4293 compared).
Modeled value ranks above 84% of those peers.
Closest niche peers: Dnanexus, Inc., Foresight Biotherapeutics, Inc., Zyomyx Inc, Champions Oncology, Inc., Thrasos Innovation Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.